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Background and objectives: Screening colonoscopy with polipectomy reduces colonorectal
cancer incidence and mortality. An adequate bowel cleansing is one of the keys to achieving
best  results with this technique. Oral sodium phosphate solution (OSP) had a widespread
use  in the 90s decade. Its efﬁcacy was similar to polyethylene glycol (PEG) solution, but with
less  cost and convenient administration. Series of patients with acute renal failure due to
OSP  use have been reported. However, large cohorts of patients found no difference in the
incidence of renal damage between these two solutions.
Methods: From 2006 to 2009 we identiﬁed twelve cases of phosphate nephropathy after
colonoscopy prepared with OSP. All patients were followed up to six months. All patients
had  received just a single dose.
Results: We analyzed 12 cases with phosphate nephropathy; three patients debuted with
AKI  and nine patients had chronic renal injury. Four cases were conﬁrmed with renal
biopsy. One patient with AKI needed hemodialysis at diagnosis without subsequent recov-
ery.  Two patients (both with chronic damage) fully recovered their previous renal function.
The  remaining patients (nine) had an average loss of estimated glomerular ﬁltration rate of
24  ml/min/1.73 m2.
Conclusions: The use of OSP can lead to both acute and chronic renal damage. However,
chronic injury was the most common pattern. Both forms of presentation imply a signiﬁcant
and  irreversible loss of renal function. Further studies analyzing renal damage secondary to
bowel cleaning should consider these two different patterns of injury. Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an©  2016 Sociedadopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Abbreviations: OSP, oral sodium phosphate; PEG, polyethylene glycol; AKI, acute kidney injury; CKD, chronic kidney disease; PN, phosphate
ephropaty; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MDRD4, modiﬁcation of the diet
n  renal disease; eGFR, estimated gomerular ﬁltration rate; Scr, serum creatinine; CHF, chronic heart failure; ESRD, end stage renal disease.
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Dan˜o  renal  después  de  preparación  colónica  con  soluciones  de  fosfato.
Más  allá  del  fracaso  renal  agudo
Palabras clave:
Insuﬁciencia renal crónica
Insuﬁciencia renal
Nefropatía
r  e  s  u  m  e  n
Antecedentes y objetivos: La colonoscopia con polipectomía con ﬁnes de cribado reduce la
incidencia del cáncer colorrectal y la mortalidad por esta enfermedad. Una preparación
colónica aceptable es una de las claves para conseguir mejores resultados con esta técnica.
Las soluciones de fosfato de sodio oral (OSP) fueron muy utilizadas en la década de los
noventa del siglo pasado. Su eﬁcacia era similar a la de las soluciones de polietilenglicol
(PEG), pero más baratas y con una administración sencilla. Se han descrito series de casos
de  pacientes con insuﬁciencia renal aguda provocada por OSP. Sin embargo, en cohortes
amplias de pacientes no se observó ninguna diferencia en la incidencia de dan˜o renal entre
estas dos soluciones.
Métodos: Entre 2006 y 2009 identiﬁcamos 12 casos de nefropatía por fosfato tras preparación
con OSP para colonoscopia. Se realizó el seguimiento de todos los pacientes durante 6 meses.
Todos los pacientes habían recibido una única dosis.
Resultados: Analizamos 12 casos de nefropatía por fosfato; 3 se manifestaron con IRA y
9  presentaron dan˜o renal crónico. Cuatro de los casos se conﬁrmaron mediante biopsia
renal. Un paciente con IRA precisó hemodiálisis en el momento del diagnóstico, sin que
experimentara recuperación posterior. Dos pacientes (ambos con dan˜o crónico) recuper-
aron  totalmente su función renal anterior. Los demás pacientes (9) presentaron una pérdida
media en la ﬁltración glomerular estimada de 24 ml/min/1,73 m2.
Conclusiones: El uso de OSP puede ocasionar dan˜o renal tanto agudo como crónico. Sin
embargo, el dan˜o crónico fue el más frecuente. Ambas formas de presentación suponen
una pérdida considerable e irreversible de función renal. Nuevos estudios que analicen el
dan˜o  renal secundario a preparación colónica deben considerar estos dos patrones distintos
de  dan˜o.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la CC BY-NC-ND licencia (http://creativecommons.org/licencias/Introduction
The use of colonoscopy for routine screening for colon and rec-
tal cancer has been one of the most successful public health
projects worldwide. Although colonoscopy is the most fre-
quent technique that requires a proper bowel preparation, it
could be necessary in others diagnosis tests: CT colonogra-
phy, barium enema and surgery on the gastrointestinal tract.
Effective preparation requires an adequate level of cleansing.
The osmotically balanced, polyethylene glycol-based elec-
trolyte solutions are elected because they are safer and faster
than large volume saline-based electrolyte solutions. Many
patients have great difﬁculty to drink the large volume, that
can result in unsuccessful preparation and poorly cleansed
colon, and therefore, inadequate study assessment.1 The
small volume of oral sodium phosphate solution (OSP) was
associated with improved patients compliance, less discom-
fort, and superior colonic cleansing.
The OSPS is not exempt from risks. It can cause transient
hyperphosphatemia and can induce intravascular volume
contraction. There have been reports of serious adverse
events, including death, and there have been case reports of
nephrocalcinosis with renal failure associated with the use
of oral sodium phosphate.2–4 In fact, in 2008 FDA issued a
warning about the use of OSP in patients with chronic kidney
disease (CKD) or major cardiovascular comorbidities.by-nc-nd/4.0/).
Unfortunately, the results of the available epidemiologic
data from large populations are quite confusing some studies
reporting a potent association5–7 and others reporting non-
signiﬁcant trends toward better kidney outcomes after OSP
compared with other purgatives.2,8 A major limitation of most
of theses studies is they just consider renal damage when
an acute renal failure happens. However the chronic dam-
age has been well documented with the use of this purgative
solution.9,10
Given the large number of patients exposed to OSP annu-
ally, clariﬁcation of this association is compelling. We  present
a series of patients with acute and chronic renal damage link
to use of OSP.
Material  and  methods
Patient  selection  and  study  design
From 2006 to 2009 we identiﬁed 12 patients with suspected
nephropathy after colonoscopy prepared by phosphosoda. The
clinical suspicion of PN (was based on the presence of an acute
o chronic renal function deterioration (>50% from basal serum
creatinine) chronologically related to colonoscopy. In all the
patients, the presence of proteinuria o hematuria was ruled
out by repeated urine analysis, also presence of urinary tract
obstruction or other urinary tract abnormalities was excluded
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Table 1 – Baseline clinical characteristics of 12 patients with phosphate nephropathy.
Age (years) Gender eGFR
(ml/min/1.73 m2)©
Hypertension Diabetes
mellitus
ACEi-ARB Diuretics Renal biopsy Course
Case 1 61 Man 63.6 No No No No Yes Acute
Case 2 85 Female 41.3 Yes Yes No Yes – Chronic
Case 3 71 Man 70.7 Yes Yes Yes Yes Yes Acute
Case 4 73 Female 73.2 Yes Yes Yes Yes – Chronic
Case 5 84 Man 59.6 Yes No Yes Yes – Chronic
Case 6 59 Female 137.9 Yes No Yes Yes – Chronic
Case 7 70 Female 95.6 Yes Yes Yes Yes Yes Chronic
Case 8 72 Man 54.5 Yes No Yes Yes – Chronic
Case 9 72 Man 54.5 Yes No Yes Yes – Acute
Case 10 73 Female 65.6 Yes No Yes No Yes Chronic
Case 11 75 Man 54.0 Yes No Yes No – Chronic
Case 12 92 Man 35.2 Yes No Yes No – Chronic
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a© Modiﬁcation of the diet in renal disease (MDRD)-4 equation was us
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II 
y appropriate radiological examinations. Patients with clin-
cal or analytical data that suggested systemic diseases were
xcluded.
All included patients had at least one Scr determination
n the three months before the colonoscopy and it was con-
idered as baseline Scr. The highest Scr value registered was
ecorded, as well as the need for acute dialysis. The cre-
tinine concentration at 6 months after the procedure was
ecorded.
Medical records of the patients were reviewed for this
tudy. We  reviewed for age, gender, medical history (high
lood pressure, smoker, hypercholesterolemia and diabetes
ellitus) and medication (ACE inhibitors, diuretics). Estimated
lomerular ﬁltration rate (eGFR) was calculated according to
he MDRD4 formula. All cases happened in a single hospital.
he Scr was measured in a single laboratory and by the kinetic
affé blank correction method.
Final Scr was deﬁned as the value obtained 6 months after
ithdrawal of the offending drug. An incomplete recovery of
aseline renal function was deﬁned by an Scr value higher
han at least 25% of the baseline value.
The recommended regimen of OSP solution (Casen Fleet
aboratories) consisted of two 45 ml  doses taken 10–12 h apart,
he evening before and the morning of colonoscopy. Each
5 ml  dose contained 21.6 g of monobasic sodium phosphate
NaH2PO4) and 8.1 g of dibasic sodium phosphate (Na2H-PO4),
hich is equivalent to 5.8 g of elemental phosphorus. The 5.8 g
f phosphorus was diluted into a single eight ounce glass and
dministered twice in a 12–24 h period (total dose 11.6 g of
hosphorus).
tatistical  analysis
he baseline characteristics are expressed as
eans ± standard deviation (SD). The groups were com-
ared using the 2-sample t test, 2-test and Fischer exact
ests, respectively. The 2-sample t test was used to compare
he creatinine level and eGFR between the study and control
roups. The 2-test was used to compare group characteristics
f diabetes, hypertension, and use of angiotensin receptor
lockers (ARBs), angiotensin-converting enzyme inhibitors
nd diuretics. P < 0.05 was considered signiﬁcant. Statistics estimate glomerular ﬁltration rate (eGFR).
tor blockers.
were calculated using SPSS for Windows, version 11 (SPSS
Inc., Chicago, IL, USA).
Results
Twelve cases of phosphate nephropathy were diagnosed: four
of them were conﬁrmed by renal biopsy. The baseline charac-
teristics of patients in both groups are shown in Table 1.
There were a predominance of cases of men, 68.2% with
mean age 69.44 ± 7.2 years. The main co-morbidities in our
patients were high blood pressure 91.6% and DM 33.3%. The
73.3% of the patients received treatment with ACE inhibitors
or ARBs, and the 66.5% received treatment with diuretics.
All patients received just one dose of OSP. None of them
were subjected to repeated cleanings intestinal in a short
period. One patient undergone endoscopy procedures during
hospitalization for acute indications (case 1). The other eleven
patients received the OSPS preparation and performed the
colonoscopy in outpatient regimen.
Kidney  function
Before the procedure, eGFR was >60 ml/min/1.73 m2 in
7 patients. CKD stage 3a was present in 3 patients and CKD
3b in 2 patients. None has CKD 4 or 5 stage.
Three patients debuted as acute renal failure (two cases
conﬁrmed with renal biopsy) and nine patients developed
chronic renal damage (two cases conﬁrmed with renal biopsy).
No signiﬁcant differences were found in the baseline renal
function, age, sex, treatment with ACEi or ARBs, diuretics,
mellitus diabetes or hypertension.
In the group of patients who debuted as AKI (acute kidney
injury), one of patients begun with nausea and vomiting hours
after colonoscopy (case 1). The others two patients debuted in
the week after the OSP administration. In the patients with
delayed debut the average time until the diagnosis was 54 days
(15–120 days). All of them were asymptomatic or pauci symp-
tomatic and the renal damage was an accidental diagnosis.
Patients presented with AKI had a higher initial loss
of glomerular ﬁltration rate, but no signiﬁcantly, than the
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Table 2 – Renal outcome in 12 patients with phosphate nephropathy.
Course Baseline eGFR
(ml/min/1.73 m2)
Peak eGFR
(ml/min/1.73 m2)
eGFR 6 month after
(ml/min/1.73 m2)
eGFR 6 m after
(ml/min/1.73 m2)
Case 1 Acute 63.6 7.9 41.6 22.0
Case 2 Chronic 41.3 30.2 48.2 −6.9
Case 3 Acute 70.7 9.9 HD HD
Case 4 Chronic 73.2 36.9 50.5 22.7
Case 5 Chronic 59.6 28.6 38.3 21.3
Case 6 Chronic 137.9 51.9 76.5 61.4
Case 7 Chronic 95.6 29.7 39.2 56.3
Case 8 Chronic 54.5 15.3 19.6 34.9
Case 9 Acute 54.5 12.8 31.5 23.0
Case 10 Chronic 65.6 8.6 27.3 38.3
Case 11 Chronic 54.0 20.7 31.0 23.1
Case 12 Chronic 35.2 18.0 23.3 11.9
Fig. 1 – Renal biopsy ﬁndings in chronic phosphate
nephropathy. (a) Case of chronic phosphate nephropathy
with abundant intraluminal and intracellular calciﬁcations
in distal tubules accompanied by tubular atrophy and
ﬁbrosis (hematoxylin and eosin) and (b) a positiveHD: hemodialysis.
patients with chronic presentation (52 ± 9.9 ml/min/1.73 m2 vs
38 ± 24 ml/min/1.72 m2, NS).
Calcium and phosphorus levels were normal in the delayed
analysis. None other alterations were ﬁnding.
Renal  follow  up
One patient of the acute course group needed substitutive
renal therapy in the moment of diagnosis, without later recov-
ery. Six months later, none of the remainder two patients
of this group recovered completely the glomerular ﬁltration
rate, although they got it partially. The ﬁnal average loss was
22.5 ± 9.7 ml/min/1.73 m2.
In the group with delayed presentation, six months later
of colonoscopy just two patients recovered renal function
as previous baseline and nine patient did not improved.
In the patients who  did not recovered baseline renal func-
tion, the ﬁnal average loss of glomerular ﬁltration rate was
26 ± 20 ml/min/1.73 m2 (Table 2).
Renal  biopsy  ﬁndings
In four patients a biopsy was performed. The renal biopsy ﬁnd-
ings in PN primary involve the tubules and were dependent on
the time interval between the preparation with oral sodium
phosphate and renal biopsy. The biopsy from patients with
AKI acute degenerative changes predominated a resemble
ﬁndings seen an acute tubular necrosis.11 The renal biopsies
performed in patients with chronic course showed tubular
atrophy and interstitial ﬁbrosis. Regardless of the degree of
acuity of chronicity, the hallmark of PN was abundant tubu-
lar and less prominent interstitial calcium phosphate deposits
(Fig. 1). The calciﬁcations do not polarize and have a strong his-
tochemical reaction with the von Kossa stain, indicating that
they are composed of calcium phosphate.
DiscussionTen years ago some cases of PN began to be published.4
The former cases were presented as an acute illness that
manifested as tetany, acute kidney disease or cardiovascular
collapse usually within hours of bowel preparation. Patients
histochemical reaction with the von Kossa stain conﬁrms
that the tubular concretions are composed of calcium
phosphate.
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ad marked hyperphosphatemia and hypocalcemia and some
atients required even hemodialysis.12
Although case reports and case series provide strong sup-
ort for an etiological relationship between OSP and the
evelopment of PN, epidemiological studies have showed less
onsistent results. In an retrospective observational study
f 9799 patients who ﬁlled a prescription for an OSP or
EG (polyethylene glycol), 114 patients (1.16%) developed AKI:
.29% of the 6432 patients who  received OSPS and 0.92% of
he 3367 patients who  received PEG. The PEG group included
atients who were signiﬁcantly older and had a higher inci-
ence of diabetes mellitus, hypertension, CHF, CKD, diuretics
se and ACEi or ARBs use (p < 0.05). In the multiple logis-
ic regression models adjusted for covariates and suspected
isk factors, OSP was found to be the strongest risk factor for
he development or AKI after colonoscopy (OR 2.35, CI 95%
.51–3.66) when compared with PEG. When a more  “strict”
eﬁnition of AKI was considered (doubling of serum creati-
ine vs >50% serum creatinine increase), the OSP purgative
se remained signiﬁcantly associated with increased risk for
KI (OR 3.52, CI 95% 1.13–10.93).5
In a recent, large retrospective cohort study using a US-
ased administrative claims database. The number of the
atients included was impressive: 121,226 received OSP pill
reparation and 429,430 received PEG. Patients were followed
p to 6 months for AKI, renal failure and dialysis. The
nvestigators did not ﬁnd any increase risk of AKI in OSP
ill users compared with PEG (0.2% vs 0.3%). The investiga-
ors acknowledged that the study of administrative claims
or AKI outcomes may be an insensitive measure of renal
ysfunction.8
Brunelli et al. undertook a systematic review and meta-
nalysis that concluded that it is not possible to discern if an
ssociation between OSP exposure and AKI exits. The use of
ifferent AKI deﬁnitions and signiﬁcant heterogeneity among
he studies referred to choice of bowel preparation, patients
opulations, baseline renal function, limited the result of the
tudy.13
The chronic form of kidney damage due to OSP agents may
resent weeks after the initial exposure and may be identi-
ed as the result of an investigation of mild or non-speciﬁc
ymptoms such as fatigue. Sometimes, it is just discovered
y a casual analysis and the anamnesis is the clue. This was
he most frequent pattern in our study. The 65% of the patients
ere referred for study by nephrologist for increasing in serum
reatinine in casual analysis.
This form of presentation requires the inclusion of this
ntity in the differential diagnosis of CKD. The nephrologist or
hysician who  treats these patients should consider the possi-
ility of PN in patients with renal damage without proteinuria
r hematuria when the patient has undergone a digestive test
repared OSD.
Whereas until now to estimate the incidence of kidney
isease for OSP we  consider just the case presented as AKI,
gnoring cases of delaying presentation. It may mean that this
roblem is more  prevalent than is currently recognized. In fact,
n the studies that analyze the safe of bowel preparation for
olonoscopy the follow up was too short to identify it.
But, the true issue of this complication is not to know the
KI incidence if the secondary chronic loss of renal function(3):243–248 247
over time. The outcomes of these patients are very incon-
stant: in most of cases of our study represent a substantial
and irreversible loss of glomerular ﬁltration. In Hurst et al.,5
just the 16% of patients returned to baseline renal function.
They could not know if any of these patients requires renal
replacement. In cases reported at least four patients developed
ESRD.14 In most of studies this information is not available. In
our study one patient (case 3) required renal replacement at
diagnosis time and she did not recover renal function. The
other patients had an average chronic loss glomerular ﬁltra-
tion > 20 ml/min/1.72 m2.
Different options to get an adequate level of cleansing, such
as PEG, can also cause renal damage.5,15 The AKI incidence
reported for PEG vary between 0.92% and 6%.  If we  consider
that the damage is mainly due to renal hypoperfusion by dehy-
dration, we could think that this injury would less severe and
more  reversible, although to our knowledge, none study has
analyzed the long lasting effect of this injury.
The presence of CKD before the colonoscopy has been con-
sidered as the most weighty risk factor to develop kidney
damage.6,14,16 However in our study the 63% of the patients
had an eGFR > 60 ml/min/1.73 m2. In fact, a lot of cases with
normal o nearly normal baseline renal function with kid-
ney injury induced OSP have been published.17 Some studies
have suggested that females, above all elderly females, are
at greater risk than males for developing PN.14 They might
have reduced renal capacity of handle a phosphate load and
their smaller body mass makes then more  sensitive to ﬂuid
loss. This loss of volumen in conjunction with limited oral
intake dictated by precolonoscopy protocols, may exacerbate
some of the electrolyte abnormalities and the risk of renal fail-
ure among patients receiving these agents. Drugs that impact
intravascular volumen and renal perfusion may increase the
risk of kidney injury after OSP use, including diuretics, ACE
inhibitors, angiotensin receptor blockers and non-steroidal
anti-inﬂammatory agents.
The standard dose of OSP contains 11.6 g of phosphorus.
About 57% of the dose is excreted in feces, 15% in urine
and 28% is retained in the body for 24 h.18 The total amount
of phosphate increases after the ﬁrst and second doses to
fourfold and eightfold of the baseline level respectably and
remains elevates at 24 h. These results suggest that the second
dose of OSP is particularly dangerous because renal reabsorp-
tion of phosphate is fully inhibited at the time of dosing and
thus the urinary concentrations of phosphate remains ele-
vated for prolonged period.
In summary, the administration of oral sodium phosphate
can cause an intense renal injury, sometimes depend of dial-
ysis and often irreversible. This side effect does not always
occur in high-risk patients and the most common pattern of
presentation was renal chronic disease. The series that study
this adverse effect should consider both the acute and chronic
pattern damage.
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